All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo, University Hospital of Salamanca, Salamanca, ES. We asked, What is new for MDS with del(5q)?
What is new for MDS with del(5q)?
In this video, Campelo discusses results from the interim analysis of the SINTRA-REV clinical trial (NCT01243476). The study confirmed that early treatment with low-dose lenalidomide delayed the time to and reduced the risk of transfusion dependency for patients with lower-risk, del(5q) MDS.
Subscribe to get the best content related to MDS delivered to your inbox